http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019009359-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c68aeaa7cae6348fee416325a7552d11 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate | 2018-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f30aa2393a44dc51458ec2cb20ab83ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ec202225cebaf643c4a93642b16666d |
| publicationDate | 2019-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019009359-A1 |
| titleOfInvention | PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION |
| abstract | The present invention relates to a technique for administering rifampicin, the technique being adapted for long-term administration by improving the direct transfer of rifampicin to the brain and suppressing the first passage to the liver. This pharmaceutical composition for nasal administration, which contains, as active ingredient, rifampicins selected from the group consisting of rifampicin, its derivatives and their salts, and is used for the prevention or treatment of dementia, is capable of long-term administration by improving the direct transfer of rifampicin to the brain and by removing the first pass to the liver. |
| priorityDate | 2017-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 411.